SYF33f9dbbe981e4da0afcbe4f30a1cc11cRegistry ID: 2025-524713-88-00|Active Not RecruitingPhase 2
Loading search results
interventional
N/A
1 country
2
To provide continued treatment with avutometinib alone or in combination with defactinib for participants with recurrent LGSOC who are deriving continued clinical benefit after completion of the RAMP-201 study.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2, 2026
Actual (reported)Investigator’s determination of ongoing clinical benefit
Frequency and severity of side effects, including abnormal findings from laboratory tests or physical examinations
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
VS-6063
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
VS-6766
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CAPSULE, HARD
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
VS-6063
Named ingredient: defactinib
View registry recordVS-6766
Named ingredient: Avutometinib
View registry recordInstitut Curie
Paris, 75005, France
Centre Leon Berard
Lyon, 69008, France
Medical Affairs
First Submitted
March 2, 2026
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.